BioSapien key facts
as of Oct 2026- Developer of a three-dimensional printed drug delivery platform designed to deliver medicines in a localized, sustained manner for cancer indications.
- BioSapien is valued at approximately $23.0M as of Oct 2026 (last reported valuation).
- It has raised $10.1M; the latest was Later Stage VC ($8.0M) in Jul 2025.
- Notable investors include US National Science Foundation, SOSV, MicroVentures, Side Door Ventures, Golden Gate Ventures — 16 tracked in total.
- Status: Privately Held (backing).
BioSapien's last reported valuation, Jul 2025. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch BioSapien: the Monday email on marks, rounds and moves
BioSapien funding rounds
No funding rounds for BioSapien are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs BioSapien
16+BioSapien valuation
BioSapien's last reported valuation was $23 million in Jul 2025. No priced round, secondary trade or fund mark has surfaced since.
BioSapien investors
16 investors are on record for BioSapien, including US National Science Foundation, SOSV, MicroVentures and Side Door Ventures. By type, the record holds 4 venture capital firms and 1 asset manager.
About BioSapien
Developer of a three-dimensional printed drug delivery platform designed to deliver medicines in a localized, sustained manner for cancer indications. The company's platform offers products that are being designed with biodegradable mesh capable of the sustained delivery of small molecules and are affixable to delicate and complex anatomy, enabling healthcare professionals to achieve efficacy while decreasing toxicity by releasing drugs directly to a cancerous tumor site.
- Sector
- Healthcare
- HQ
- Carlsbad, CA, United States
- Founded
- 2018
- Employees
- 10
- Website
- biosapien.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.